![](/images/graphics-bg.png)
Potential Survival Benefit of Anti-Apoptosis Protein: Survivin-Derived Peptide Vaccine with and without Interferon Alpha Therapy for Patients with Advanced or Recurrent Urothelial Cancer—Results from Phase I Clinical Trials
المؤلفون المشاركون
Inoue, Ryuta
Masumori, Naoya
Torigoe, Toshihiko
Nishida, Sachiyo
Kitamura, Hiroshi
Tsukamoto, Taiji
Tanaka, Toshiaki
Sato, Noriyuki
Kawami, Sachiyo
Hirohashi, Yoshihiko
Takahashi-Takaya, Akari
المصدر
Journal of Immunology Research
العدد
المجلد 2013، العدد 2013 (31 ديسمبر/كانون الأول 2013)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2013-11-20
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
We previously identified a human leukocyte antigen (HLA)-A24-restricted antigenic peptide, survivin-2B80–88, a member of the inhibitor of apoptosis protein family, recognized by CD8+cytotoxic T lymphocytes (CTL).
In a phase I clinical trial of survivin-2B80-88 vaccination for metastatic urothelial cancer (MUC), we achieved clinical and immunological responses with safety.
Moreover, our previous study indicated that interferon alpha (IFNα) enhanced the effects of the vaccine for colorectal cancer.
Therefore, we started a new phase I clinical trial of survivin-2B80–88 vaccination with IFNα for MUC patients.
Twenty-one patients were enrolled and no severe adverse event was observed.
HLA-A24/survivin-2B80–88 tetramer analysis and ELISPOT assay revealed a significant increase in the frequency of the peptide-specific CTLs after vaccination in nine patients.
Six patients had stable disease.
The effects of IFNα on the vaccination were unclear for MUC.
Throughout two trials, 30 MUO patients received survivin-2B80–88 vaccination.
Patients receiving the vaccination had significantly better overall survival than a comparable control group of MUO patients without vaccination (P=0.0009).
Survivin-2B80–88 vaccination may be a promising therapy for selected patients with MUC refractory to standard chemotherapy.
This trial was registered with UMIN00005859.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Tanaka, Toshiaki& Kitamura, Hiroshi& Inoue, Ryuta& Nishida, Sachiyo& Takahashi-Takaya, Akari& Kawami, Sachiyo…[et al.]. 2013. Potential Survival Benefit of Anti-Apoptosis Protein: Survivin-Derived Peptide Vaccine with and without Interferon Alpha Therapy for Patients with Advanced or Recurrent Urothelial Cancer—Results from Phase I Clinical Trials. Journal of Immunology Research،Vol. 2013, no. 2013, pp.1-9.
https://search.emarefa.net/detail/BIM-1006517
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Tanaka, Toshiaki…[et al.]. Potential Survival Benefit of Anti-Apoptosis Protein: Survivin-Derived Peptide Vaccine with and without Interferon Alpha Therapy for Patients with Advanced or Recurrent Urothelial Cancer—Results from Phase I Clinical Trials. Journal of Immunology Research No. 2013 (2013), pp.1-9.
https://search.emarefa.net/detail/BIM-1006517
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Tanaka, Toshiaki& Kitamura, Hiroshi& Inoue, Ryuta& Nishida, Sachiyo& Takahashi-Takaya, Akari& Kawami, Sachiyo…[et al.]. Potential Survival Benefit of Anti-Apoptosis Protein: Survivin-Derived Peptide Vaccine with and without Interferon Alpha Therapy for Patients with Advanced or Recurrent Urothelial Cancer—Results from Phase I Clinical Trials. Journal of Immunology Research. 2013. Vol. 2013, no. 2013, pp.1-9.
https://search.emarefa.net/detail/BIM-1006517
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1006517
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)